AstraZeneca

Open: 63.86 Close: 63.96 Change: 0.1

Our AI found some flaws in AstraZeneca.

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, development, PLC, Cellectis, gene, candidate, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

AstraZeneca has signed a joint research collaboration agreement with Cellectis to develop up to ten cell and gene therapy candidates. Company announced closure of research and development activities at Alderley Park in Cheshire and Loughborough in the UK and at Lund in Sweden.

Today's News

AstraZeneca has signed a joint research collaboration agreement with Cellectis to develop up to ten cell and gene therapy candidates. The $80 million equity investment will be spent on 16 million ordinary shares, giving AstraZeca a 22% stake in the biotech, along with 21% of voting rights. GlobalDatas Pharmaceutical Intelligence Centre forecasts the total worldwide sales of Lokelma at around $799m in 2029. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. Company also owns BreacherEyelaus Levelocrinrams festive merch 110 Ot AstraZeneca announced plans for a major corporate restructuring in March 2013. Company announced closure of research and development activities at Alderley Park in Cheshire and Loughborough in the UK and at Lund in Sweden. AstraZeneca has its headquarters in Cambridge, United Kingdom, and main R&D centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) In August 2012, Pascal Soriot was named CEO. AstraZeneca agreed to pay £505 million to settle a UK tax dispute related to transfer mispricing in 2010. The company declared towards the European Commission and the EU member states: 13.1 AstraZeneca underwrites Cambridge-Sweden flights. AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips. Oxford vaccine researchers have found winning formula AstraZeneca PLC ADR falls Friday, underperforms market Nov. ET by MarketWatch Automation. Cellectis stock is biggest gainer and most active premarket after equity investment, collaboration pact. AstraZeneca bid to block Medicare price talks Barred, HHS says. HHS: Inflation Reduction Act bans judicial review, HHS asserts AstraZecas says implementation violates APA. HHS urges court to toss the APA claims and enter a judgment in its favor. Astrazeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca in 1999. AstraZeneca says FluMist has shown to be as effective as other flu vaccines. FDA reviewing application for nasal spray flu vaccine FluMist to be able to be self-administered at home. Patients would still need to go through an online pharmacy system. AstraZeneca to invest $245 million in Cellectis to boost gene therapy prospects. Deal aimed at speeding up the development of therapeutics in areas including oncology, immunology and rare diseases. Agreement grants Astrazeneca exclusive access to up to 25 genetic targets, with up to 10 candidates in development. AstraZeneca PLC AZN, -1.22% AZN: +1.45% said Tuesday the U.S. Food and Drug Administration accepts for review its Flumist self-administered flu vaccine. AstraZeneca PLC ADR AZN dropped 0.34% to $63.96 Friday, on what proved to be an all-around favorable trading session for the stock market. AstraZecas has kicked off late-stage trial assessing MEDI5752 in combination With carboplatin plus pemetrexed in unresectable Pleural Mesothelioma. Astrazeneca (AZN) stock is on an upward trajectory this year. AstraZeneca/Mercks Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer. Astrazeneca is projected to report earnings of $0.79 per share, which would represent a year-over-year decline of 5.95% Investors should also pay attention to any latest changes in analyst estimates. AstraZeneca is currently a Zacks Rank #3 (Hold) AstraZeneca will leverage Cellectis proprietary gene editing technologies to design novel cell and gene therapy candidate products. 25 genetic targets have been exclusively reserved for Astra Zeneca, from which up to 10 candidate products could be explored for development.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, development, PLC, Cellectis, gene, candidate, and the most common words in the summary are: astrazeneca, company, news, cellectis, drug, say, vaccine, . One of the sentences in the summary was: Company announced closure of research and development activities at Alderley Park in Cheshire and Loughborough in the UK and at Lund in Sweden.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #company #news #cellectis #drug #say #vaccine.